<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Tazarotene: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Tazarotene: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Tazarotene: Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="9665" href="/d/html/9665.html" rel="external">see "Tazarotene: Drug information"</a> and <a class="drug drug_patient" data-topicid="11876" href="/d/html/11876.html" rel="external">see "Tazarotene: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F224840"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Arazlo;</li>
<li>Avage [DSC];</li>
<li>Fabior;</li>
<li>Tazorac</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52868334"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Arazlo;</li>
<li>Tazorac [DSC]</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F1050155"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Acne Products</span>;</li>
<li>
<span class="list-set-name">Keratolytic Agent</span></li></ul></div>
<div class="block dop drugH1Div" id="F224855"><span class="drugH1">Dosing: Pediatric</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> In patients experiencing excessive pruritus, burning, skin redness, or peeling, discontinue until integrity of the skin is restored or reduce dosing to an interval the patient is able to tolerate.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a14813b8-cfac-43a7-8cfe-083e79bea0fc">Acne vulgaris</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Acne vulgaris:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Cream or gel: Children ≥12 years and Adolescents: Topical: Tazorac (0.1%): Apply as a thin film (2 mg/cm<sup>2</sup>) to affected area(s) once daily in the evening.</p>
<p style="text-indent:-2em;margin-left:4em;">Foam: Children ≥12 years and Adolescents: Topical: Fabior (0.1%): Apply a small amount to affected area(s) once daily in the evening.</p>
<p style="text-indent:-2em;margin-left:4em;">Lotion: Children ≥9 years and Adolescents: Topical: Arazlo (0.045%): Apply a thin layer to affected area(s) once daily.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="9c51dc6e-ca0a-48cc-bfad-6cb5d9403c14">Psoriasis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Psoriasis:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Cream: Adolescents ≥18 years: Topical: Tazorac (0.05%): Initial: Apply a thin film (2 mg/cm<sup>2</sup>) to affected area once daily in the evening; may increase strength to 0.1% if tolerated and necessary.</p>
<p style="text-indent:-2em;margin-left:4em;">Gel: Children ≥12 years and Adolescents: Topical: Tazorac (0.05%): Initial: Apply a thin film (2 mg/cm<sup>2</sup>) to affected area once daily in the evening; may increase strength to 0.1% if tolerated and necessary; apply to no more than 20% of the body surface area.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="8c6afec2-bc0b-4019-a29f-d7c8c335b021">Palliation of fine facial wrinkles, facial mottled hyper-/hypopigmentation, benign facial lentigines</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Palliation of fine facial wrinkles, facial mottled hyper-/hypopigmentation, benign facial lentigines:</b> Adolescents ≥17 years: Topical: Cream: Avage (0.1%): Apply a pea-sized amount once daily at bedtime; lightly cover entire face including eyelids if desired.</p></div>
</div>
</div>
<div class="block dorp drugH1Div" id="F51191950"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; however, dosage adjustment unlikely necessary due to low systemic absorption.</p></div>
<div class="block dohp drugH1Div" id="F51191951"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; however, dosage adjustment unlikely necessary due to low systemic absorption.</p></div>
<div class="block doa drugH1Div" id="F224843"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="9665" href="/d/html/9665.html" rel="external">see "Tazarotene: Drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a14813b8-cfac-43a7-8cfe-083e79bea0fc">Acne vulgaris</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Acne vulgaris:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> For moderate to severe acne, may be used as part of an appropriate combination regimen (AAD [Zaenglein 2016]). Consider starting with the lowest possible concentration to minimize skin irritation and increase potency as tolerated. In patients experiencing excessive pruritus, burning, skin redness, or peeling, discontinue until integrity of the skin is restored, or reduce dosing to an interval the patient can tolerate.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Topical:</b></p>
<p style="text-indent:-2em;margin-left:6em;">Arazlo: Apply a thin layer to affected area once daily.</p>
<p style="text-indent:-2em;margin-left:6em;">Fabior: Apply a small amount to affected area once daily in the evening.</p>
<p style="text-indent:-2em;margin-left:6em;">Tazorac cream/gel 0.05% or 0.1%: Apply a thin layer (2 mg/cm<sup>2</sup>) to affected area once daily in the evening.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="8c6afec2-bc0b-4019-a29f-d7c8c335b021">Palliation of fine facial wrinkles, facial mottled hyper-/hypopigmentation, benign facial lentigines</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Palliation of fine facial wrinkles, facial mottled hyper-/hypopigmentation, benign facial lentigines:</b>
<b>Topical:</b> Avage: Apply a pea-sized amount to entire face once daily at bedtime. In patients experiencing excessive pruritus, burning, skin redness, or peeling, discontinue until integrity of the skin is restored, or reduce dosing to an interval the patient can tolerate.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="9c51dc6e-ca0a-48cc-bfad-6cb5d9403c14">Psoriasis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Psoriasis:</b>
<b>Topical:</b> Tazorac cream/gel: Initial: 0.05%: Apply once daily in the evening to psoriatic lesions using enough (2 mg/cm<sup>2</sup>) to cover only the lesion with a thin film. May increase strength to 0.1% if tolerated and necessary. In patients experiencing excessive pruritus, burning, skin redness, or peeling, discontinue until integrity of the skin is restored, or reduce dosing to an interval the patient can tolerate.</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F50991490"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doha drugH1Div" id="F50988848"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block adr drugH1Div" id="F224812"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Percentage of incidence varies with formulation and/or strength.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%: Dermatologic: Desquamation (0.1% cream 40%; foam 6%), erythema (0.1% cream 34%; foam 6%), burning sensation of skin (26%), xeroderma (7% to 16%), skin irritation (10% to 14%), exacerbation of psoriasis, skin pain</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Peripheral edema</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Pruritus (0.1% cream 10%; foam 1%), contact dermatitis (8%), stinging of the skin (3%), skin rash (≤3%), cheilitis (1%), dermatitis (1%), skin photosensitivity (1%), eczema, skin discoloration, skin fissure</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Hypertriglyceridemia</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Application site pain (1%), local hemorrhage</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Ocular irritation (including edema, irritation, and inflammation of the eye or eyelid; 4%)</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined: Hypersensitivity: Hypersensitivity reaction, local hypersensitivity reaction</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%, postmarketing, and/or case reports: Application site edema, exfoliation of skin, impetigo, pain, skin blister</p></div>
<div class="block coi drugH1Div" id="F224826"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity to tazarotene or any component of the formulation; pregnancy.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling:</i> Additional contraindications (not in the US labeling): Presence of seborrheic dermatitis.</p></div>
<div class="block war drugH1Div" id="F224809"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Photosensitivity: May cause photosensitivity; exposure to ultraviolet rays (including sunlight/sunlamps) should be avoided unless deemed medically necessary, and in such cases, exposure should be minimized. Risk may be increased by concurrent therapy with known photosensitizers (thiazides, tetracyclines, fluoroquinolones, phenothiazines, sulfonamides); use with caution. Use with caution in patients with a personal or family history of skin cancer. Daily sunscreen use and other protective measures recommended. Patients with sunburn should discontinue use until sunburn has healed.</p>
<p style="text-indent:-2em;margin-left:4em;">• Skin irritation: Local tolerability reactions (including blistering or skin desquamation) or local hypersensitivity reactions (including urticaria) may occur. Application-site pain, excessive burning, drying, pruritus, peeling, and skin redness may occur, especially during the early weeks of treatment. Treatment can increase skin sensitivity to weather extremes of wind or cold. Concomitant topical medications (eg, medicated or abrasive soaps, cleansers, cosmetics with a strong drying effect) should be avoided due to increased skin irritation. Depending on the severity of the reaction, instruct patients to use a moisturizer, reduce the frequency of use, or discontinue use.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Benzyl alcohol and derivatives: Some dosage forms may contain benzyl alcohol; large amounts of benzyl alcohol (≥99 mg/kg/day) have been associated with a potentially fatal toxicity (“gasping syndrome”) in neonates; the “gasping syndrome” consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension, and cardiovascular collapse (AAP ["Inactive" 1997]; CDC 1982); some data suggests that benzoate displaces bilirubin from protein binding sites (Ahlfors 2001); avoid or use dosage forms containing benzyl alcohol with caution in neonates. See manufacturer's labeling.</p>
<p style="text-indent:-2em;margin-left:4em;">• Foam: Propellant is flammable; avoid fire and smoking during and immediately after use.</p>
<p style="text-indent:-2em;margin-left:4em;">• Gel: Safety and efficacy of gel applied over &gt;20% of BSA have not been established.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use: For external use only; avoid contact with eyes, eyelids, and mouth. Not for use on eczematous, abraded, broken, or sunburned skin; not for treatment of lentigo maligna. Avoid application over extensive areas. The efficacy of tazarotene gel in the treatment of acne previously treated with other retinoids or resistant to oral antibiotics has not been established.</p></div>
<div class="block foc drugH1Div" id="F224820"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Cream, External: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Avage: 0.1% (30 g [DSC]) [contains benzyl alcohol]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Tazorac: 0.05% (30 g [DSC], 60 g [DSC]) [contains benzyl alcohol]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Tazorac: 0.05% (30 g, 60 g) [contains benzyl alcohol, edetate (edta) disodium]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Tazorac: 0.1% (30 g [DSC], 60 g [DSC]) [contains benzyl alcohol]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Tazorac: 0.1% (30 g, 60 g) [contains benzyl alcohol, edetate (edta) disodium]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 0.1% (30 g, 60 g)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Foam, External: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Fabior: 0.1% (50 g, 100 g)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 0.1% (50 g)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Gel, External: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Tazorac: 0.05% (30 g [DSC], 100 g [DSC]) [contains benzyl alcohol]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Tazorac: 0.05% (30 g, 100 g) [contains benzyl alcohol, edetate (edta) disodium]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Tazorac: 0.1% (30 g [DSC], 100 g [DSC]) [contains benzyl alcohol]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Tazorac: 0.1% (30 g, 100 g) [contains benzyl alcohol, edetate (edta) disodium]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 0.05% (30 g, 100 g); 0.1% (30 g, 100 g)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Lotion, External: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Arazlo: 0.045% (45 g) [contains edetate (edta) disodium dihydrate, methylparaben, propylparaben]</p></div>
<div class="block geq drugH1Div" id="F224805"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">May be product dependent</p></div>
<div class="block fee drugH1Div" id="F224827"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Cream</b> (Tazarotene External)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.1% (per gram): $12.99 - $13.01</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Cream</b> (Tazorac External)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.05% (per gram): $19.19</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.1% (per gram): $20.38</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Foam</b> (Fabior External)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.1% (per gram): $17.81</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Foam</b> (Tazarotene External)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.1% (per gram): $16.01</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Gel</b> (Tazarotene External)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.05% (per gram): $15.80</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.1% (per gram): $16.79</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Gel</b> (Tazorac External)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.05% (per gram): $19.19</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.1% (per gram): $20.38</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Lotion</b> (Arazlo External)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.045% (per gram): $14.27</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52868335"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Cream, External: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Tazorac: 0.05% ([DSC]); 0.1% ([DSC]) [contains benzyl alcohol]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Gel, External: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Tazorac: 0.05% ([DSC]); 0.1% ([DSC])</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Lotion, External: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Arazlo: 0.045% (3 g, 45 g) [contains edetate (edta) disodium dihydrate, methylparaben, propylparaben]</p></div>
<div class="block admp drugH1Div" id="F52613898"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">For topical use only; not for oral, ophthalmic, or intravaginal use. Avoid eyes, mouth, or other mucous membranes; rinse thoroughly with water if contact occurs. Do not cover treated areas with dressings or bandages. Do not apply to eczematous, abraded, broken, or sunburned skin. Use effective sunscreen and wear protective clothing during treatment. Wash hands after use.</p>
<p style="text-indent:-2em;margin-left:2em;">Acne:</p>
<p style="text-indent:-2em;margin-left:4em;">Cream (Tazorac), foam, gel: Apply in evening after gently cleansing and drying face; apply enough to cover entire affected area.</p>
<p style="text-indent:-2em;margin-left:4em;">Foam: Wash with a mild cleanser and dry affected area before applying foam. Shake can before use then dispense a small amount of foam into palm of the hand. Use fingertips to lightly cover the entire affected area of the face and/or upper trunk with a thin layer; massage into skin until foam disappears. Moisturizer may be used if necessary.</p>
<p style="text-indent:-2em;margin-left:4em;">Lotion: Apply thin layer to cover affected area.</p>
<p style="text-indent:-2em;margin-left:2em;">Palliation of fine facial wrinkles, facial mottled hyper-/hypopigmentation, benign facial lentigines: Cream (Avage): Apply to clean, dry face at bedtime; lightly cover entire face including eyelids if desired. Emollients or moisturizers may be applied before or after; if applied before tazarotene, ensure cream or lotion has absorbed into the skin and has dried completely before applying tazarotene.</p>
<p style="text-indent:-2em;margin-left:2em;">Psoriasis: Cream (Tazorac), gel: Apply in evening. If a bath or shower is taken prior to application, dry the skin before applying. If emollients are used, apply them at least 1 hour prior to application. Unaffected skin may be more susceptible to irritation; avoid application to these areas.</p></div>
<div class="block adm drugH1Div" id="F224823"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Topical:</b> For topical use only; not for oral, ophthalmic, or intravaginal use. Avoid eyes, mouth, paranasal creases, or other mucous membranes; rinse thoroughly with water if contact occurs. Do not cover treated areas with dressings or bandages. Do not apply to eczematous, abraded, broken, or sunburned skin. Use effective sunscreen and wear protective clothing during treatment. Wash hands after use.</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">Acne: Apply in evening after gently cleansing and drying face; apply enough to cover entire affected area. If concomitant use with oxidizing agents (eg, benzoyl peroxide) is needed, apply each medication at different times of the day (eg, one in the morning and the other in the evening); concurrent use may decrease efficacy of tazarotene containing products.</p>
<p style="text-indent:-2em;margin-left:4em;">Foam: Dispense a small amount of foam into palm of the hand. Use fingertips to lightly cover the entire affected area of the face and/or upper trunk with a thin layer; massage into skin until foam disappears. Moisturizer may be used if necessary.</p>
<p style="text-indent:-2em;margin-left:2em;">Palliation of fine facial wrinkles, facial mottled hyper-/hypopigmentation, benign facial lentigines: Apply to clean dry face at bedtime; lightly cover entire face including eyelids if desired. Emollients or moisturizers may be applied before or after; ensure first cream or lotion has absorbed into the skin and has dried completely before applying tazarotene.</p>
<p style="text-indent:-2em;margin-left:2em;">Psoriasis: Apply in evening. If a bath or shower is taken prior to application, dry the skin before applying. If emollients are used, apply them at least 1 hour prior to application. Unaffected skin may be more susceptible to irritation, avoid application to these areas.</p></div>
<div class="block sts drugH1Div" id="F224837"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:-2em;margin-left:2em;">Cream: Store at 25°C (77°F); excursions are permitted between -5°C to 30°C (23°F to 86°F).</p>
<p style="text-indent:-2em;margin-left:2em;">Foam: Store at 20°C to 25°C (68°F to 77°F); excursions are permitted between 15°C to 30°C (59°F to 86°F). Store upright and protect from freezing. Foam is flammable; avoid fire, flame, or smoking during and immediately following application. Contents under pressure. Do not puncture or incinerate. Do not expose to heat or store at temperatures above 49°C (120°F).</p>
<p style="text-indent:-2em;margin-left:2em;">Gel: Store at 20°C to 25°C (68°F to 77°F); excursions are permitted between 15°C to 30°C (59°F to 86°F).</p>
<p style="text-indent:-2em;margin-left:2em;">Lotion: Store at 20°C to 25°C (68°F to 77°F); excursions are permitted between 15°C to 30°C (59°F to 86°F); protect from freezing.</p></div>
<div class="block usep drugH1Div" id="F53569006"><span class="drugH1">Use</span>
<p style="text-indent:-2em;margin-left:2em;">Treatment of acne vulgaris (Arazlo [0.045%] lotion: FDA approved in ages ≥9 years and adults; Fabior [0.1%] foam, Tazorac [0.1%] cream, Tazorac [0.1%] gel: FDA approved in ages ≥12 years and adults).</p>
<p style="text-indent:-2em;margin-left:2em;">Treatment of plaque psoriasis (Tazorac [0.05% and 0.1%] gel: FDA approved in ages ≥12 years and adults; Tazorac [0.05% and 0.1%] cream: FDA approved in ages ≥18 years and adults).</p>
<p style="text-indent:-2em;margin-left:2em;">Mitigation (palliation) of facial fine wrinkling, facial mottled hyper-/hypopigmentation, and benign facial lentigines as adjunct to comprehensive skin care and sunlight avoidance (Avage [0.1%] cream: FDA approved in ages ≥17 years and adults).</p></div>
<div class="block cyt drugH1Div" id="F13300105"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F224814"><span class="drugH1">Drug Interactions</span>
<br/><br/><div class="clear"></div><p style="text-indent:0em;display:inline">There are no known significant interactions.</p></div>
<div class="block rep_considerations drugH1Div" id="F53083309"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">Evaluate pregnancy status prior to use in females of reproductive potential. A negative pregnancy test should be obtained within 2 weeks prior to treatment; treatment should begin during a normal menstrual period. Adequate contraception should be used in females of reproductive potential.</p></div>
<div class="block pri drugH1Div" id="F224828"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Use in pregnancy is contraindicated.</p>
<p style="text-indent:0em;margin-top:2em;">Inadvertent exposure to a limited number of pregnant women occurred during premarketing studies; however, the available data are inadequate to evaluate outcomes. Based on data from animal reproduction studies, retinoid pharmacology, and the potential for systemic absorption, in utero exposure to tazarotene may cause fetal harm.</p>
<p style="text-indent:0em;margin-top:2em;">Topical products are recommended as initial therapy for the treatment of acne or psoriasis in pregnant women. Because the safety of tazarotene is uncertain, use during pregnancy is contraindicated (Bae 2012; Chien 2016; Kong 2013).</p></div>
<div class="block mopp drugH1Div" id="F53569005"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Disease severity in plaque psoriasis (reduction in erythema, scaling, induration); pregnancy test prior to treatment of females of childbearing age.</p></div>
<div class="block pha drugH1Div" id="F224808"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Synthetic, acetylenic retinoid which modulates differentiation and proliferation of epithelial tissue and exerts some degree of anti-inflammatory and immunological activity</p></div>
<div class="block phk drugH1Div" id="F224825"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Onset of action: Psoriasis: 1 week</p>
<p style="text-indent:-2em;margin-left:2em;">Duration: Therapeutic: Psoriasis: Effects have been observed for up to 3 months after a 3-month course of topical treatment</p>
<p style="text-indent:-2em;margin-left:2em;">Absorption: Minimal following cutaneous application (≤6% of dose)</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: Retained in skin for prolonged periods after topical application</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: &gt;99% (tazarotenic acid)</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Prodrug, rapidly metabolized via esterase hydrolysis to an active metabolite (tazarotenic acid) following topical application and systemic absorption; tazarotenic acid undergoes further hepatic metabolism</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination:</p>
<p style="text-indent:-2em;margin-left:4em;">Cream, gel: ~18 hours (tazarotenic acid)</p>
<p style="text-indent:-2em;margin-left:4em;">Foam: 8.1 ± 3.7 hours</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine and feces (as metabolites)</p></div>
<div class="block phksp drugH1Div" id="F53992932"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Pediatric: Arazlo: In patients 9 to &lt;12 years of age, mean tazarotenic acid C<sub>max</sub> is ~2.4-fold higher and mean AUC (0-t) is ~2.3-fold higher compared to patients ≥12 years of age.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F224829"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Anapsor</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Zorac</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Tazoskin | Zaroten</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Zorac</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Zorac</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Aguder</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Le wei | Que wei</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Rantric | Tazat</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Tazorac</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Zorac</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Tazret</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Tazret</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Acnitaz | Palizage | Sabotaz | Tazaro | Topinoid | Zaro | Zarojel | Zarotex</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Zorac</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Zorac</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Zorac</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Zorac</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Zorac</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Tazorac | Zorac</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Zorac</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">A-ret-tz | La tez | Tazo tene | Tazoderm | Tazotop | Tazret | Texara | Zorotene</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Suretin | Zorac</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Zorac</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Zorac</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Zorac</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Marzoten f | Suretin | Tazmeral</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Tazret</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Tazret</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Taz | Tazaro | Tazret</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Zorac</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Arazlo | Avage | Tazorac</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Evitar</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Zorac</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Tazared | Tazotene | Zorante</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Ful Lee | Karac | Tarac | Tazarol | Tazorac</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Rantric</span>;</li>
<li>
<span class="countryCode">(VN)</span> <span class="country">Viet Nam</span><span class="countrySeparator">: </span><span class="drugName">Glentaz</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Zorak</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-11487763">
<a name="11487763"></a>Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. <i>J Pediatr</i>. 2001;139(2):317-319.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tazarotene-pediatric-drug-information/abstract-text/11487763/pubmed" id="11487763" target="_blank">11487763</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Arazlo (tazarotene) [prescribing information]. Bridgewater, NJ: Bausch Health US LLC; December 2019.</div>
</li>
<li>
<div class="reference">
                  Arazlo (tazarotene) [product monograph]. Laval, Quebec, Canada: Bausch Health, Canada Inc; July 2021.</div>
</li>
<li>
<div class="reference">
                  Avage (tazarotene) [prescribing information]. Irvine, CA: Allergan Inc; July 2017.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22018758">
<a name="22018758"></a>Bae YS, Van Voorhees AS, Hsu S, et al; National Psoriasis Foundation. Review of treatment options for psoriasis in pregnant or lactating women: from the Medical Board of the National Psoriasis Foundation. <i>J Am Acad Dermatol</i>. 2012;67(3):459-477. doi:10.1016/j.jaad.2011.07.039<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tazarotene-pediatric-drug-information/abstract-text/22018758/pubmed" id="22018758" target="_blank">22018758</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24528912">
<a name="24528912"></a>Butler DC, Heller MM, Murase JE. Safety of dermatologic medications in pregnancy and lactation: Part II. Lactation. <i>J Am Acad Dermatol</i>. 2014;70(3):417.e1-e10; quiz 427. doi:10.1016/j.jaad.2013.09.009<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tazarotene-pediatric-drug-information/abstract-text/24528912/pubmed" id="24528912" target="_blank">24528912</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6810084">
<a name="6810084"></a>Centers for Disease Control (CDC). Neonatal deaths associated with use of benzyl alcohol—United States. <i>MMWR Morb Mortal Wkly Rep</i>. 1982;31(22):290-291. <a href="https://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm" target="_blank">http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm</a>
<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tazarotene-pediatric-drug-information/abstract-text/6810084/pubmed" id="6810084" target="_blank">6810084</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26957383">
<a name="26957383"></a>Chien AL, Qi J, Rainer B, Sachs DL, Helfrich YR. Treatment of acne in pregnancy. <i>J Am Board Fam Med</i>. 2016;29(2):254-262. doi:10.3122/jabfm.2016.02.150165<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tazarotene-pediatric-drug-information/abstract-text/26957383/pubmed" id="26957383" target="_blank">26957383</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Fabior (tazarotene) [prescribing information]. Greenville, NC: Mayne Pharma; June 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9024461">
<a name="9024461"></a>"Inactive" ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics (AAP) Committee on Drugs. <i>Pediatrics</i>. 1997;99(2):268-278.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tazarotene-pediatric-drug-information/abstract-text/9024461/pubmed" id="9024461" target="_blank">9024461</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23657872">
<a name="23657872"></a>Kong YL, Tey HL. Treatment of acne vulgaris during pregnancy and lactation. <i>Drugs</i>. 2013;73(8):779-787. doi:10.1007/s40265-013-0060-0<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tazarotene-pediatric-drug-information/abstract-text/23657872/pubmed" id="23657872" target="_blank">23657872</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26131868">
<a name="26131868"></a>Kurizky PS, Ferreira Cde C, Nogueira LS, Mota LM. Treatment of psoriasis and psoriatic arthritis during pregnancy and breastfeeding. <i>An Bras Dermatol</i>. 2015;90(3):367-375. doi:10.1590/abd1806-4841.20153113<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tazarotene-pediatric-drug-information/abstract-text/26131868/pubmed" id="26131868" target="_blank">26131868</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16677965">
<a name="16677965"></a>Leachman SA, Reed BR. The use of dermatologic drugs in pregnancy and lactation. <i>Dermatol Clin</i>. 2006;24(2):167-197, vi. doi:10.1016/j.det.2006.01.001<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tazarotene-pediatric-drug-information/abstract-text/16677965/pubmed" id="16677965" target="_blank">16677965</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Tazorac cream (tazarotene) [prescribing information]. Exton, PA: Almirall LLC; August 2019.</div>
</li>
<li>
<div class="reference">
                  Tazorac cream (tazarotene) [product monograph]. Markham, Ontario, Canada: Allergan Inc; December 2015.</div>
</li>
<li>
<div class="reference">
                  Tazorac gel (tazarotene) [prescribing information]. Exton, PA: Almirall LLC; August 2019.</div>
</li>
<li>
<div class="reference">
                  Tazorac gel (tazarotene) [product monograph]. Markham, Ontario, Canada: Allergan Inc; June 2015.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26897386">
<a name="26897386"></a>Zaenglein AL, Pathy AL, Schlosser BJ, et al. Guidelines of care for the management of acne vulgaris. <i>J Am Acad Dermatol. </i>2016;74(5):945-973.e33. doi:10.1016/j.jaad.2015.12.037<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tazarotene-pediatric-drug-information/abstract-text/26897386/pubmed" id="26897386" target="_blank">26897386</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 13004 Version 267.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
